271 related articles for article (PubMed ID: 22275465)
1. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
Gill KL; Houston JB; Galetin A
Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465
[TBL] [Abstract][Full Text] [Related]
2. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
Cubitt HE; Houston JB; Galetin A
Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618
[TBL] [Abstract][Full Text] [Related]
3. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
[TBL] [Abstract][Full Text] [Related]
4. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
[TBL] [Abstract][Full Text] [Related]
5. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.
Soars MG; Burchell B; Riley RJ
J Pharmacol Exp Ther; 2002 Apr; 301(1):382-90. PubMed ID: 11907196
[TBL] [Abstract][Full Text] [Related]
6. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
Naritomi Y; Nakamori F; Furukawa T; Tabata K
Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
[TBL] [Abstract][Full Text] [Related]
7. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
[TBL] [Abstract][Full Text] [Related]
8. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.
Furukawa T; Nakamori F; Tetsuka K; Naritomi Y; Moriguchi H; Yamano K; Terashita S; Teramura T
Drug Metab Pharmacokinet; 2012; 27(2):171-80. PubMed ID: 21970858
[TBL] [Abstract][Full Text] [Related]
9. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.
Rowland A; Knights KM; Mackenzie PI; Miners JO
Drug Metab Dispos; 2008 Jun; 36(6):1056-62. PubMed ID: 18362158
[TBL] [Abstract][Full Text] [Related]
10. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
Gaganis P; Miners JO; Knights KM
Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.
Badée J; Qiu N; Parrott N; Collier AC; Schmidt S; Fowler S
Drug Metab Dispos; 2019 Feb; 47(2):124-134. PubMed ID: 30478159
[TBL] [Abstract][Full Text] [Related]
12. Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.
Knights KM; Spencer SM; Fallon JK; Chau N; Smith PC; Miners JO
Br J Clin Pharmacol; 2016 Jun; 81(6):1153-64. PubMed ID: 26808419
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.
Knights KM; Winner LK; Elliot DJ; Bowalgaha K; Miners JO
Br J Clin Pharmacol; 2009 Sep; 68(3):402-12. PubMed ID: 19740398
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9.
Kishi N; Takasuka A; Kokawa Y; Isobe T; Taguchi M; Shigeyama M; Murata M; Suno M; Hanioka N
Xenobiotica; 2016; 46(4):289-95. PubMed ID: 26247833
[TBL] [Abstract][Full Text] [Related]
15. In vitro glucuronidation of propofol in microsomal fractions from human liver, intestine and kidney: tissue distribution and physiological role of UGT1A9.
Mukai M; Tanaka S; Yamamoto K; Murata M; Okada K; Isobe T; Shigeyama M; Hichiya H; Hanioka N
Pharmazie; 2014 Nov; 69(11):829-32. PubMed ID: 25985579
[TBL] [Abstract][Full Text] [Related]
16. Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.
Manevski N; Moreolo PS; Yli-Kauhaluoma J; Finel M
Drug Metab Dispos; 2011 Nov; 39(11):2117-29. PubMed ID: 21856742
[TBL] [Abstract][Full Text] [Related]
17. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine.
Docci L; Umehara K; Krähenbühl S; Fowler S; Parrott N
AAPS J; 2020 Oct; 22(6):128. PubMed ID: 33033903
[TBL] [Abstract][Full Text] [Related]
18. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
[TBL] [Abstract][Full Text] [Related]
19. 6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1
Lapham K; Lin J; Novak J; Orozco C; Niosi M; Di L; Goosen TC; Ryu S; Riccardi K; Eng H; Cameron KO; Kalgutkar AS
Drug Metab Dispos; 2018 Dec; 46(12):1836-1846. PubMed ID: 30194276
[TBL] [Abstract][Full Text] [Related]
20. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Cubitt HE; Houston JB; Galetin A
Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
